* Texas Biotechnology Corp., Houston, will separate on Nov. 7 the4 million units issued in conjunction with its initial public offeringin December 1993. The company said it exercised its option toseparate the units, with consent of underwriter D. Blech & Co.,earlier than the original one-year anniversary date of Dec. 15, 1994.* American Biogenetic Sciences Inc., Copiague, N.Y., said it iscutting its workforce 40 percent. It refused to provide additionaldetails to BioWorld.* Abaxis Inc., of Sunnyvale, Calif., has raised $9.4 million throughthe sale of 2.35 million shares of common stock. Proceeds from thestock sale will be used to fund commercialization of the company'sVetScan and to seek regulatory approval for its Piccolo bloodanalysis system.* Deprenyl Animal Health Inc., of Overland Park, Kan., filed aregulatory application with the Canadian Health ProtectionBranch's Bureau of Veterinary Drugs to market Anipryl for canineCushing's disease. The new drug submission is the company's first.* Aprogenex Inc., Houston, entered a development collaborationwith an unnamed European manufacturer of instruments for cellseparation.* Imagenetics, Framingham, Mass., announced at the meeting of theAmerican Society of Human Genetics that it changed its name toVysis Inc.* Lexin Pharmaceutical Corp., Horsham, Pa., signed a collaborativeresearch and licensing agreement with Wichita State (Kan.)University for exclusive rights to small molecule compoundssynthesized there by William Groutas.* Vanguard Medica Ltd., Guildford, U.K., said it received aninvestment of about $3.1 million from Allstate Venture Capital, and$2.4 million from existing investors.* Cytel Corp., San Diego, was awarded a $1.6 million contract bythe National Institutes of Health to expand its Theradigmtechnology. The contract covers five years.* Bio-Technology General Corp., Iselin, N.J., said its human growthhormone product was launched in Germany. It was launched in theNetherlands in September.

(c) 1997 American Health Consultants. All rights reserved.